← Nanobiotix S.A.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income | — | — | — | — | — | ($57.0m) |
($39.7m)
+30.40%
|
($68.1m)
-71.62%
|
($24.0m)
+64.83%
|
($24.0m)
0.00%
|
|
| Net loss for the period | — | ($30.3m) | ($50.9m) | ($33.6m) | ($47.0m) | ($57.0m) | ($39.7m) | ($68.1m) | ($24.0m) | — | |
| Impact of the Janssen amendment on profit or loss | — | — | — | — | — | — | $0 | $23.4m | ($21.5m) | — | |
| Profit or Loss | — | — | ($50.9m) | ($33.6m) | ($47.0m) | ($57.0m) | ($39.7m) | ($68.1m) | ($24.0m) | — | |
| Depreciation and amortization | — | $619k | $1.8m | $1.8m | $1.6m | $1.5m | $1.5m | $1.6m | $1.5m | $1.5m | |
| Depreciation Amortization Depletion | — | — | — | — | — | $1.5m | $1.5m | $1.6m | $1.5m | $1.5m | |
| Deferred Income Tax | — | — | — | — | $0 | $0 | $120k | $101k | $3k | $3k | |
| Deferred Tax | — | — | — | — | — | $0 | $120k | $101k | $3k | $3k | |
| Adjustments For Share-Based Payments | — | — | $4.3m | $2.9m | $3.2m | $3.2m | $3.2m | $4.3m | $3.5m | — | |
| Expenses related to share-based payments | — | $1.9m | $4.3m | $2.9m | $3.2m | $3.2m | $3.2m | $4.3m | $3.5m | — | |
| Cash flows from (used in) operations, before tax and changes in working capital | — | ($27.1m) | ($39.6m) | ($33.3m) | ($41.4m) | ($39.4m) | ($22.4m) | ($33.8m) | ($29.8m) | — | |
| Change In Working Capital | — | — | — | — | — | $2.3m | $9.9m | $14.3m | ($3.4m) | ($3.4m) | |
| (Increase) / Decrease in trade receivables | — | $144k | ($85k) | ($51k) | $62k | ($101k) | ($806k) | ($2.1m) | $840k | — | |
| Increase in other receivables | — | ($4.0m) | ($4.6m) | ($721k) | ($5.0m) | ($4.2m) | ($4.4m) | ($1.5m) | ($2.1m) | — | |
| Change In Receivables | — | — | — | — | — | ($1.8m) | ($1.1m) | $355k | $1.9m | $1.9m | |
| Changes In Account Receivables | — | — | — | — | — | ($101k) | ($806k) | ($2.1m) | $840k | $1.9m | |
| Increase / (Decrease) in trade and other payables | — | $633k | $2.1m | ($995k) | ($281k) | $2.9m | $8.7m | $2.0m | ($5.4m) | — | |
| Increase / (Decrease) in other current liabilities | — | $999k | $1.1m | $1.8m | ($1.7m) | $1.2m | $723k | ($224k) | $175k | — | |
| Change In Other Current Liabilities | — | — | — | — | — | $1.2m | $723k | ($224k) | $175k | $175k | |
| Acquisitions of property, plant and equipment | — | ($416k) | ($1.1m) | ($96k) | ($228k) | ($92k) | ($328k) | ($846k) | ($538k) | — | |
| Capital Expenditure | — | — | — | — | — | ($93k) | ($337k) | ($848k) | ($546k) | ($546k) | |
| Acquisitions of intangible assets | — | ($90k) | ($353k) | ($11k) | ($5k) | ($1k) | ($9k) | ($2k) | ($8k) | — | |
| Net cash flows from (used in) investing activities | — | $71k | ($1.5m) | ($112k) | ($242k) | $138k | ($349k) | ($955k) | ($578k) | — | |
| Proceeds From Borrowings Classified As Financing Activities | — | — | $14.0m | $10.3m | $0 | $0 | $150k | $0 | $42.9m | — | |
| Repayments Of Borrowings Classified As Financing Activities | — | — | — | — | $2.8m | $3.6m | $3.0m | $3.1m | $3.5m | — | |
| Cost of net debt | — | $292k | $1.9m | $2.1m | $2.2m | $2.0m | $2.7m | $1.9m | $4.1m | — | |
| Issuance Of Debt | — | — | — | — | — | $0 | $150k | $0 | $42.9m | $42.9m | |
| Long Term Debt Issuance | — | — | — | — | — | $0 | $150k | $0 | $42.9m | $42.9m | |
| Net Issuance Payments Of Debt | — | — | — | — | — | ($4.7m) | ($3.6m) | ($4.2m) | $38.2m | $38.2m | |
| Net Long Term Debt Issuance | — | — | — | — | — | ($4.7m) | ($3.6m) | ($4.2m) | $38.2m | $38.2m | |
| Long Term Debt Payments | — | — | — | — | — | ($4.7m) | ($3.8m) | ($4.2m) | ($4.7m) | ($4.7m) | |
| Repayment Of Debt | — | — | — | — | — | ($4.7m) | ($3.8m) | ($4.2m) | ($4.7m) | ($4.7m) | |
| Issuance Of Capital Stock | — | — | — | — | — | $0 | $60.2m | $0 | $1.5m | $1.5m | |
| Common Stock Issuance | — | — | — | — | — | $0 | $60.2m | $0 | $1.5m | $1.5m | |
| Cash Dividends Paid | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Net Other Financing Charges | — | — | — | — | ($349k) | ($1k) | ($2.8m) | — | ($778k) | ($778k) | |
| Net cash flows from (used in) financing activities | — | $14.8m |
$41.5m
+179.39%
|
$111.8m
+169.39%
|
($5.2m)
-104.63%
|
($5.7m)
-9.09%
|
$46.8m
+927.66%
|
($5.1m)
-110.98%
|
$37.4m
+828.65%
|
— | |
| Net increase (decrease) in cash and cash equivalents | — | ($11.0m) | ($1.1m) | $84.1m | ($35.2m) | ($42.5m) | $33.9m | ($25.5m) | $3.0m | — | |
| Beginning Cash Position | — | — | — | — | — | $83.9m | $41.4m | $75.3m | $49.7m | $49.7m | |
| Net cash and cash equivalents at beginning of period | $47.2m | $36.2m | $35.1m | $119.2m | $83.9m | $41.4m | $75.3m | $49.7m | $52.8m | — | |
| Effect of exchange rates changes on cash | — | $54k | $29k | ($63k) | $64k | $83k | ($51k) | $94k | ($402k) | — | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | $83k | ($51k) | $94k | ($402k) | ($402k) | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Changes in operating working capital | — | $1.1m | ($1.5m) | $5.8m | $11.5m | $2.3m | $9.9m | $14.3m | ($3.4m) | — | |
| Additional Financial Items | |||||||||||
| Adjustments For Decrease Increase In Trade Account Receivable | — | — | ($85k) | ($51k) | $62k | ($101k) | ($806k) | ($2.1m) | $840k | — | |
| Adjustments For Finance Costs | — | — | $1.9m | $2.1m | $2.2m | $2.0m | $2.7m | $1.9m | $4.1m | — | |
| Increase Decrease In Working Capital | — | — | $1.5m | ($5.8m) | ($11.5m) | ($2.3m) | ($9.9m) | ($14.3m) | $3.4m | ($3.4m) | |
| Payments Of Lease Liabilities Classified As Financing Activities | — | — | $1.1m | $928k | $909k | $1.1m | $794k | $1.1m | $1.2m | — | |
| Proceeds From Issuing Shares | — | — | — | $113.3m | — | — | — | — | — | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | — | — | $353k | $11k | $5k | $1k | $9k | $2k | $8k | — | |
| Provisions | — | $5k | $164k | ($48k) | $152k | $305k | $506k | ($263k) | ($225k) | — | |
| Loss on disposal | — | $0 | $45k | $0 | $0 | $3k | ($24k) | ($3k) | $153k | — | |
| Impact of discounting financial liabilities and amortized cost | — | — | $2.8m | ($6.5m) | ($1.6m) | $10.6m | $5.0m | $3.3m | $6.8m | — | |
| Other non cash income and expenses | — | ($36k) | ($5k) | $7k | $8k | ($36k) | $4.3m | $0 | ($160k) | — | |
| Receipt of research tax credit receivable | — | $3.3m | $0 | $5.7m | $1.9m | $2.5m | $4.1m | $3.9m | $3.1m | — | |
| Increase in deferred income and contract liabilities | — | — | $0 | $0 | $16.5m | $0 | $1.6m | $12.2m | ($16k) | — | |
| (Increase) / Decrease in non-current financial assets | — | $577k | ($16k) | ($4k) | ($9k) | $230k | $12k | $107k | ($32k) | — | |
| Capital increases | — | $0 | $29.5m | $113.7m | $0 | $0 | $60.2m | $0 | $1.5m | — | |
| Transaction costs | — | ($279k) | ($1.4m) | ($10.4m) | ($349k) | $0 | ($2.8m) | $0 | ($777k) | — | |
| Increase in loans - Royalty Financing | — | $16.0m | $14.0m | $10.3m | $0 | $0 | $150k | $0 | $42.9m | — | |
| Increase in other loans and conditional advances | — | — | — | — | — | — | $150k | $0 | $0 | — | |
| Loan repayments | — | — | ($500k) | ($250k) | ($2.8m) | ($3.6m) | ($3.0m) | ($3.1m) | ($3.5m) | — | |
| Payment of lease liabilities | — | $0 | ($1.1m) | ($928k) | ($909k) | ($1.1m) | ($794k) | ($1.1m) | ($1.2m) | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | ($5.7m) | $46.8m | ($5.1m) | $37.4m | $37.4m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | $137k | ($349k) | ($955k) | ($578k) | ($578k) | |
| Change In Other Working Capital | — | — | — | — | $16.5m | — | $1.6m | $12.2m | ($16k) | ($16k) | |
| Change In Payable | — | — | — | — | — | $2.9m | $8.7m | $2.0m | ($5.4m) | ($5.4m) | |
| Changes In Cash | — | — | — | — | — | ($42.6m) | $33.9m | ($25.6m) | $3.4m | $3.4m | |
| End Cash Position | — | — | — | — | — | $41.4m | $75.3m | $49.7m | $52.8m | $52.8m | |
| Financing Cash Flow | — | — | — | — | — | ($5.7m) |
$46.8m
+927.66%
|
($5.1m)
-110.98%
|
$37.4m
+828.65%
|
$37.4m
+0.00%
|
|
| Free Cash Flow | — | — | — | — | — | ($37.2m) | ($12.8m) | ($20.4m) | ($34.0m) | ($34.0m) | |
| Investing Cash Flow | — | — | — | — | — | $138k | ($349k) | ($955k) | ($578k) | ($578k) | |
| Net Intangibles Purchase And Sale | — | — | — | — | — | ($1k) | ($9k) | ($2k) | ($8k) | ($8k) | |
| Net PPE Purchase And Sale | — | — | — | — | — | ($92k) | ($328k) | ($846k) | ($538k) | ($538k) | |
| Operating Gains Losses | — | — | — | — | — | $3k | ($24k) | ($3k) | $153k | $153k | |
| Other Non Cash Items | — | — | — | — | — | $12.7m | $12.0m | $28.6m | ($10.8m) | — | |
| Proceeds From Stock Option Exercised | — | — | — | — | $43k | $0 | $0 | — | — | $0 | |
| Provisionand Write Offof Assets | — | — | — | — | — | $305k | $506k | ($263k) | ($225k) | ($225k) | |
| Purchase Of Intangibles | — | — | — | — | — | ($1k) | ($9k) | ($2k) | ($8k) | ($8k) | |
| Purchase Of PPE | — | — | — | $96k | $228k | ($92k) | ($328k) | ($846k) | ($538k) | ($546k) | |
| Stock Based Compensation | — | — | — | — | — | $3.2m | $3.2m | $4.3m | $3.5m | $3.5m | |
| Net Investment Purchase And Sale | — | — | — | — | — | $230k | ($12k) | ($107k) | ($32k) | ($32k) | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | ($42.5m) | $33.9m | ($25.5m) | $3.0m | — | |
| Interest Paid Classified As Financing Activities | — | ($3k) | $350k | $700k | $1.1m | $915k | $7.0m | $980k | $1.5m | — | |
| Tax paid | — | — | — | — | $0 | $0 | ($7k) | ($62k) | ($198k) | — |